title: Perception of alopecia by patients requiring chemotherapy for non-small-cell lung cancer: a willingness to pay study.
abstract: OBJECTIVE
  Chemotherapy-induced alopecia may have a substantial impact on the quality of life (QOL) of lung cancer patients, but very few data are available. The aim of this study was to assess the perceived impact of alopecia based on a "willingness to pay" (WTP) approach.
  
  
  METHODS
  We conducted a prospective multicenter WTP study of patients receiving chemotherapy for non-small-cell lung cancer (NSCLC). The perceived impact of alopecia was assessed with a visual analogue scale (VAS; 0: no impact, 10: major impact), and from the patients' willingness to pay for chemotherapy that had the same efficacy, dosing schedule and tolerability as the standard treatment but that cut the risk of alopecia from 40% to 5%.
  
  
  RESULTS
  Among the 135 patients enrolled in this study, the mean score on the VAS for the perceived likely impact of alopecia was 4.4 ± 0.3. The mean WTP for a 3-week chemotherapy cycle reducing the risk of alopecia from 40% to 5% was €83.4 ± 10.2 (€median 37.5), representing 2.1% of total income, while 27% of patients were unwilling to pay anything. There was a significant association between WTP and gender (women, p < 0.01), annual incomes (p < 0.01), but not with marital status, level of education or occupations.
  
  
  CONCLUSIONS
  Alopecia appears to be an important outcome for patients receiving chemotherapy for NSCLC. Women and patients with high annual incomes were more willing to pay.
authors.affiliation: Pharmacy, Hôpital Bichat-Claude Bernard, APHP, 46 rue Henri Huchard, 75877 Paris Cedex 18, France. melisande.bernard@bch.aphp.fr
authors.forename: Mélisande
authors.initials: M
authors.lastname: Bernard
authors.forename: Mélanie
authors.initials: M
authors.lastname: Brignone
authors.forename: Alain
authors.initials: A
authors.lastname: Adehossi
authors.forename: Samuel
authors.initials: S
authors.lastname: Pefoura
authors.forename: Caroline
authors.initials: C
authors.lastname: Briquet
authors.forename: Christos
authors.initials: C
authors.lastname: Chouaid
authors.forename: Patrick
authors.initials: P
authors.lastname: Tilleul
mesh_terms: D000505:Alopecia / Q000523:psychology*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000523:psychology*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000523:psychology*; D008297:Male; D008875:Middle Aged; D010465:Perception; D011446:Prospective Studies; D011788:Quality of Life; D011795:Surveys and Questionnaires
chemical_list: D000970:Antineoplastic Agents